Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.3 - $3.01 $52,708 - $122,040
-40,545 Reduced 36.62%
70,174 $101,000
Q1 2024

May 13, 2024

SELL
$1.71 - $3.07 $76,392 - $137,149
-44,674 Reduced 28.75%
110,719 $246,000
Q4 2023

Feb 13, 2024

BUY
$1.39 - $2.35 $56,535 - $95,581
40,673 Added 35.45%
155,393 $301,000
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $166,344 - $384,312
114,720 New
114,720 $168,000
Q1 2023

May 12, 2023

BUY
$1.97 - $3.58 $533,846 - $970,137
270,988 Added 1734.21%
286,614 $676,000
Q4 2022

Feb 14, 2023

BUY
$2.78 - $8.09 $43,440 - $126,414
15,626 New
15,626 $54,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.